Brind.
  1. Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
  2. Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.

Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.

2 reports, 0 independent Updated Jul 2
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.

Who's involved

What this event is mainly about
Ligand Pharmaceuticals

Keep exploring

Part of

Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales. All 1 developments

Within Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet